Chronic Obstructive Pulmonary Disease Forecast and Market Analysis to 2026: Triple Therapies will Drive Modest Growth of the COPD Market – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Chronic Obstructive Pulmonary Disease Forecast and Market Analysis to 2026” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Chronic obstructive pulmonary disease (COPD) is defined by persistent airflow limitation (reduction in the ability to exhale at a normal rate and volume). While chronic and progressive dyspnea (shortness of breath) is a key symptom, patients may also present with productive cough. Significant exposure to noxious particles or gases, namely tobacco smoke, is the primary cause of the underlying alveolar and airway abnormalities that result in the airflow limitation and respiratory symptoms that characterize the disease. However, other environmental and occupational exposures or genetic abnormalities may also contribute to symptoms.

Latest Key Takeaways

• The report estimates that in 2018, there were approximately 307.0 million prevalent cases of chronic obstructive pulmonary disease (COPD) worldwide, and forecasts that number to increase to 328.9 million prevalent cases by 2027.
• The “ABCD” GOLD treatment guidelines focus on exacerbation risk and patient-reported outcomes to determine pharmacological treatment strategies, independent of spirometric value.
• Dual bronchodilator combinations are being considered as the new gold standard over long-acting muscarinic antagonist (LAMA) Spiriva in the treatment of more severe COPD.
• Triple inhaled corticosteroid/long-acting beta 2 agonist/long-acting muscarinic antagonist (ICS/LABA/LAMA) fixed-dose combination therapies delivered through a single inhaler bring convenience to more severe patients. For Breztri Aerosphere’s FDA submission, AstraZeneca included data from the KRONOS study, but the ETHOS trial did not complete primary endpoints until mid-2019. As such, the FDA issued a complete response letter to AstraZeneca, benefitting rival GlaxoSmithKline’s marketed Trelegy Ellipta as the only triplet on the US market. More recently, Breztri has gained approval in the US and Europe.
• IL-5 inhibitors have disappointed in the broader population of more severe COPD patients. However, ongoing studies are evaluating AstraZeneca’s Fasenra and GlaxoSmithKline’s Nucala in individuals with high eosinophils. Topline results from Fasenra’s RESOLUTE and Nucala’s MATINEE trials are expected in the coming years, while Phase III results from Sanofi and Regeneron’s dual IL-4 and IL-13 inhibitor Dupixent are expected in 2023.
• Nebulizers are limited by convenience and often are being developed by smaller companies that lack the commercial resources of large pharma.

Key Topics Covered:

OVERVIEW

• Latest key takeaways

DISEASE BACKGROUND

• Disease definition
• Diagnosis
• Patient segmentation
• GOLD treatment recommendations

TREATMENT

• Maintenance treatment
• Oral therapies for maintenance treatment
• Non-pharmacological management of COPD

EPIDEMIOLOGY

• Prevalence methodology

MARKETED DRUGS

PIPELINE DRUGS

KEY REGULATORY EVENTS

• Hikma Launches Long-Awaited US Advair Rival
• Trixeo Aerosphere Wins EMA Thumbs Up
• US FDA Panel Rejects Trelegy Ellipta COPD Mortality Claim; Worries Include Potential Overuse
• Cipla Files ANDA For Advair Rival; FDA Will Now Consider Indian Firm’s Version Alongside Hikma
• Can Glenmark’s Triple Therapy Combo Move COPD Treatment Needle?
• String Of Positives For Lupin Lifts Outlook
• Cipla Granted Approval For First US Proventil Rival
• Mylan Launches Advair Rival In Canada

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

• Iconovo And Amneal Collaborate On Symbicort Rival
• Circassia Ends AZ Deal To Dig Itself Out Of Debt Hole

CLINICAL TRIAL LANDSCAPE

• Sponsors by status
• Sponsors by phase
• Recent events

DRUG ASSESSMENT MODEL

• LAMAs
• LABAs
• LABA/LAMAs
• ICS/LABAs
• ICS/LABA/LAMAs
• Biologics
• PDE3/4 inhibitor

MARKET DYNAMICS

FUTURE TRENDS

• Triple therapies will drive modest growth of the COPD market
• The impact of nebulized treatment is limited
• Biologics present an opportunity that is limited to certain patient subsets

CONSENSUS FORECASTS

RECENT EVENTS AND ANALYST OPINION

• Trelegy Ellipta for COPD (August 31, 2020)
• Trelegy Ellipta for COPD (August 28, 2020)
• Breztri Aerosphere for COPD (June 24, 2020)
• RPL554 (Inhaled) for COPD (March 31, 2020)
• Breztri Aerosphere for COPD (October 1, 2019)

KEY UPCOMING EVENTS

UNMET NEEDS

• Characterizing patient subpopulations
• Developing more effective means of managing exacerbations
• Improving inhaler technique and compliance

BIBLIOGRAPHY

• Prescription information

APPENDIX

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/f6gx05

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900